Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.50 |
| ▸ | CTRC | Q99895 | 6/20 | 0.49 |
| ▸ | CMA1 | P23946 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239360 | 0.89 | CMA1 (0.53) | ELANECTRCCMA1HSD17B10 | |
| SCHEMBL6803001 | 0.88 | ELANE (0.60) | ELANECTRCCMA1ALDH1A1HPGD | |
| SCHEMBL6802606 | 0.88 | ELANE (0.47) | ELANECTRCCMA1ALDH1A1POLB | |
| SCHEMBL6799136 | 0.88 | ELANE (0.47) | ELANECTRCCMA1POLBAPEX1 | |
| Hydrochloric Acid SCHEMBL6805327 | 0.87 | CMA1 (0.53) | ELANECTRCCMA1HSD17B10 | |
| SCHEMBL6804111 | 0.87 | CMA1 (0.53) | ELANECTRCCMA1HSD17B10 | |
| SCHEMBL6805368 | 0.87 | ELANE (0.53) | ELANECTRCCMA1 | |
| SCHEMBL6804320 | 0.83 | ELANE (0.44) | ELANECTRCCMA1MEN1ALDH1A1 | |
| SCHEMBL6804164 | 0.80 | CMA1 (0.48) | ELANECTRCCMA1 | |
| SCHEMBL6800734 | 0.79 | GAA (0.40) | ELANECTRCCMA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | ELANE 4400/4885CTRC 2595/4885CMA1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.